<DOC>
	<DOC>NCT01460654</DOC>
	<brief_summary>This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.</brief_summary>
	<brief_title>Testosterone and Alendronate in Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male sex Age 60 or above Testosterone &lt;300 ng/dL DXA T score &lt; 1 OR FRAX Score of 3% or greater for hip fracture or 20% or greater for major osteoporotic fracture Significant liver or kidney disease Elevated prolactin level Abnormal TSH Abnormal 25Vitamin D PSA &gt; 2.5 History of malignancy Calcium &gt; 10.6 Alkaline Phosphatase &gt; 150 Fracture within the last 6 months History of acute urinary retention Hematocrit &lt; 32% or &gt; 50% Fracture within the past 6 months American Urological Association BPH symptom index &gt; 21 Sleep apnea Abnormalities of the esophagus which delay esophageal emptying Significant cardiopulmonary disease</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>